New drug combo targets Hard-to-Treat lung cancer
NCT ID NCT07549061
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug called vebreltinib combined with standard chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has MET overexpression and no other known genetic drivers. The study will enroll 19 participants to see if the combination shrinks tumors and controls the disease. It aims to find a better option for this specific group of lung cancer patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vebreltinib (a targeted drug) combined with platinum-based chemotherapy
What this could lead to
If successful, this could offer a new first-line treatment option for people with a specific type of advanced lung cancer that has MET overexpression.
What could go wrong
This is a small, early-phase trial with only 19 participants, so results may not apply to everyone. The drug combination may cause side effects or not work better than standard chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
241 West Huaihai Road, Xuhui District, Shanghai, 200030, China.
Shanghai, Shanghai Municipality, China